Introducing Converge: Connecting the Brightest Minds in Technology and Life Sciences

Introducing Converge: Connecting the Brightest Minds in Technology and Life Sciences

By Michelle Nemits, Executive Director, Bay Area, Biocom California?


With the convergence of the traditional biotech sector and the Silicon Valley tech industry, we are seeing an ever-faster pace of innovation leading to tremendous breakthroughs across the healthcare landscape. The leadership of this rapidly converging ecosystem is found in California, the birthplace of biotech and home to Silicon Valley.?

It is against this backdrop that we announce Converge by Biocom California, a cross-sector community where the brightest minds in technology and life sciences will gather to shape and navigate new frontiers in healthcare. ??

As a convening organization for the #lifescience industry, Biocom California extends an invitation to the #tech and #medtech communities to join us in a collaborative 3-way partnership working to accelerate innovation, drug discovery, healthcare solutions and accessibility for patients globally.?

Our recent panel in South San Francisco on bridging AI and biotechnology was an enlightening event that delved deep into the realm of AI and its profound impact on the ever-evolving fields of biomedicine and healthcare delivery. From left to right: Michelle Nemits, executive director, Bay Area, Biocom California; Olof Mollstedt, co-founder, Alixia; Ajamete Kaykas, chief exploration officer and head of neuroscience, insitro; Kristina Kitko, associate director of venture science, Eli Lilly; Kevin Parker, co-founder and CEO, Cartography Biosciences; Renee Yao, ecosystems business development and healthcare life sciences, NVIDIA.?


The three sectors are already innovating around artificial intelligence, machine learning, and rapid computational approaches to everything from drug discovery to patient stratification, to clinical trial development, to improving operational efficiencies that unleash resources for more rapid innovation. Companies are now focusing as much on chips and computing power as on chemists and compounds.?

New approaches to harnessing big data, improving telehealth, revolutionizing wearable devices, transforming implantable diagnostics and optimizing therapeutics will change how patients receive and access care. Through #ConvergebyBiocom, we are embarking on a series of conversations to:?

  • Cultivate community?
  • Break down barriers?
  • Lead the way to the future of healthcare?

In the past few weeks, we’ve hosted two important conversations on how AI/ML is impacting the entire biopharma value chain—from drug discovery and development, clinical trials, operations, manufacturing and quality, and delivery of care to patients in the hospital setting.?Our panelists included representatives from gilead, GSK, pangaea data, ucsf, insitro, NVIDIA, alixia, lilly and cartography, and each is playing a unique role in this new era of digital transformation.?

Tech executives, life science professionals, medtech experts, healthcare providers, academic institutions, investors and payors are all invited to join this conversation. Become a member of our Converge community here on LinkedIn?to share insights and stay informed of upcoming events, networking opportunities, and news. We look forward to staying in touch!


#BiotechInnovation #ConvergeByBiocom #LifeSciences #BiocomCalifornia #Collaboration #InnovationInBiotech?

要查看或添加评论,请登录

Biocom California的更多文章

社区洞察

其他会员也浏览了